<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 19 Mar 2025 18:16:11 +0000</lastbuilddate>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>In memoriam: Ioanna Andreadou (1965-2025)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105888/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 19:ehaf066. doi: 10.1093/eurheartj/ehaf066. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105888/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105888</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf066>10.1093/eurheartj/ehaf066</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105888</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Petra Kleinbongard</dc:creator>
<dc:creator>Coert J Zuurbier</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>In memoriam: Ioanna Andreadou (1965-2025)</dc:title>
<dc:identifier>pmid:40105888</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf066</dc:identifier>
</item>
<item>
<title>EuroEcho-Imaging 2024: a global forum for echocardiography</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105883/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 19:ehaf101. doi: 10.1093/eurheartj/ehaf101. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105883/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105883</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf101>10.1093/eurheartj/ehaf101</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105883</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Denisa Muraru</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:creator>Victoria Delgado</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>EuroEcho-Imaging 2024: a global forum for echocardiography</dc:title>
<dc:identifier>pmid:40105883</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf101</dc:identifier>
</item>
<item>
<title>Leadless pacing: a comprehensive review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105878/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>Over the past decade, leadless pacing has undergone a rapid evolution, resulting in multiple leadless pacemaker (LPM) devices that offer advancements such as atrioventricular synchronized pacing in VDD mode, atrial stimulation, dual-chamber pacing, and longer battery longevity. Studies comparing LPMs with transvenous pacemakers (TVPMs) show a lower rate of device-related complications with LPMs. In the near future, LPMs could be combined with other devices such as non-transvenous implantable...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 19:ehaf119. doi: 10.1093/eurheartj/ehaf119. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Over the past decade, leadless pacing has undergone a rapid evolution, resulting in multiple leadless pacemaker (LPM) devices that offer advancements such as atrioventricular synchronized pacing in VDD mode, atrial stimulation, dual-chamber pacing, and longer battery longevity. Studies comparing LPMs with transvenous pacemakers (TVPMs) show a lower rate of device-related complications with LPMs. In the near future, LPMs could be combined with other devices such as non-transvenous implantable cardioverter-defibrillators to provide anti-tachycardia pacing or bradycardia pacing. Future prospectives for leadless cardiac resynchronization therapy and leadless conduction system pacing are being investigated. As LPMs continue to improve, their applications are anticipated to expand further improving patient outcome, promising a bright future for leadless pacing. In this review, the past, present, and future of leadless pacing are discussed with a focus on cutting-edge implantation techniques, clinical outcomes, and modern advancements of LPMs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105878/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105878</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf119>10.1093/eurheartj/ehaf119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105878</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Shmaila Saleem-Talib</dc:creator>
<dc:creator>Crispijn P R Hoevenaars</dc:creator>
<dc:creator>Nadine Molitor</dc:creator>
<dc:creator>Vincent J van Driel</dc:creator>
<dc:creator>Jeroen van der Heijden</dc:creator>
<dc:creator>Alexander Breitenstein</dc:creator>
<dc:creator>Harry van Wessel</dc:creator>
<dc:creator>Mathijs S van Schie</dc:creator>
<dc:creator>Natasja M S de Groot</dc:creator>
<dc:creator>Hemanth Ramanna</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leadless pacing: a comprehensive review</dc:title>
<dc:identifier>pmid:40105878</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf119</dc:identifier>
</item>
<item>
<title>Peak Oxygen Uptake vs Ventilatory Efficiency</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19. doi: 10.1001/jamacardio.2025.0216. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105857</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0216>10.1001/jamacardio.2025.0216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105857</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jiawei Du</dc:creator>
<dc:creator>Jinghua Hou</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Peak Oxygen Uptake vs Ventilatory Efficiency</dc:title>
<dc:identifier>pmid:40105857</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0216</dc:identifier>
</item>
<item>
<title>Peak Oxygen Uptake Vs Ventilatory Efficiency-In Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105850/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19. doi: 10.1001/jamacardio.2025.0219. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105850/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105850</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0219>10.1001/jamacardio.2025.0219</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105850</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Matthew M Y Lee</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Peak Oxygen Uptake Vs Ventilatory Efficiency-In Reply</dc:title>
<dc:identifier>pmid:40105850</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0219</dc:identifier>
</item>
<item>
<title>A Man in His 30s With Ponytail Coronary Artery Anomaly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19. doi: 10.1001/jamacardio.2025.0124. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105836</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0124>10.1001/jamacardio.2025.0124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105836</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Leizhi Ku</dc:creator>
<dc:creator>Xiaojing Ma</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Man in His 30s With Ponytail Coronary Artery Anomaly</dc:title>
<dc:identifier>pmid:40105836</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0124</dc:identifier>
</item>
<item>
<title>Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Genetically predicted lower APOC3 was associated with a reduced risk of CHD that is comparable with that associated with lower PCSK9 per unit decrease in ApoB. Combined exposure to APOC3 and LDL-C-lowering variants was associated with an additive reduction in CHD risk. Future studies are warranted to investigate the therapeutic potential of these combined therapies, particularly among high-risk patients who cannot achieve therapeutic targets with existing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19. doi: 10.1001/jamacardio.2025.0195. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3 are currently underway.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate whether genetically predicted lower APOC3 is associated with a reduction in cardiovascular risk and if the combined exposure to APOC3 and LDL-C-lowering variants is associated with a reduction in the risk of coronary heart disease (CHD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a population-based genetic association study with 2 × 2 factorial mendelian randomization. Included were participants of European ancestry in the UK Biobank. Data were analyzed from November 2023 to July 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Genetic scores were constructed to mimic the effects of APOC3, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Plasma lipid and lipoprotein levels, CHD, and type 2 diabetes (T2D).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 401 548 UK Biobank participants (mean [SD] age, 56.9 [8.0] years; 216 901 female [54.0%]). Genetically predicted lower APOC3 was associated with a lower risk of CHD (odds ratio [OR], 0.96; 95% CI, 0.93-0.98) and T2D (0.97; 95% CI, 0.95-0.99). Genetically lower APOC3 and PCSK9 were associated with a similar magnitude of risk reduction in CHD per 10-mg/dL decrease in apolipoprotein B (ApoB) level (APOC3: 0.70; 95% CI, 0.59-0.83; PCSK9: 0.71; 95% CI, 0.65-0.77). Combined exposure to genetically lower APOC3 and PCSK9 was associated with an additive lower risk of CHD (APOC3: 0.96; 95% CI, 0.92-0.99; PCSK9: 0.93; 95% CI, 0.90-0.97; combined: 0.90; 95% CI, 0.86-0.93). Genetically lower HMGCR was also associated with a lower risk of CHD, and the risk was further reduced when combined with APOC3 (0.93; 95% CI, 0.90-0.97).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Genetically predicted lower APOC3 was associated with a reduced risk of CHD that is comparable with that associated with lower PCSK9 per unit decrease in ApoB. Combined exposure to APOC3 and LDL-C-lowering variants was associated with an additive reduction in CHD risk. Future studies are warranted to investigate the therapeutic potential of these combined therapies, particularly among high-risk patients who cannot achieve therapeutic targets with existing lipid-lowering therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105833</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0195>10.1001/jamacardio.2025.0195</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105833</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Wenxiu Wang</dc:creator>
<dc:creator>Rui Li</dc:creator>
<dc:creator>Zimin Song</dc:creator>
<dc:creator>Ninghao Huang</dc:creator>
<dc:creator>Tao Huang</dc:creator>
<dc:creator>Xinwei Hua</dc:creator>
<dc:creator>Yi-Da Tang</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease</dc:title>
<dc:identifier>pmid:40105833</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0195</dc:identifier>
</item>
<item>
<title>JAMA Cardiology Peer Reviewers in 2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19:e250242. doi: 10.1001/jamacardio.2025.0242. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105831</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0242>10.1001/jamacardio.2025.0242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105831</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology Peer Reviewers in 2024</dc:title>
<dc:identifier>pmid:40105831</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0242</dc:identifier>
</item>
<item>
<title>Concomitant Mechanical Aspiration and Appendage Closure for Recalcitrant Left Atrial Appendage Thrombi</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105811/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This cases series found that temporary cerebral protection, percutaneous mechanical vacuum thrombectomy, and mechanical LAA closure was feasible in patients with persistent LAA thrombus despite optimal OAC. Larger studies will be needed to fully assess the efficacy and safety of this approach.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19. doi: 10.1001/jamacardio.2025.0203. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: It is well appreciated that a small yet high-risk subset of patients with atrial fibrillation (AF) develops persistent left atrial appendage (LAA) thrombus despite optimal oral anticoagulation (OAC). In patients with either a heightened risk of bleeding precluding enhanced doses of OAC to dissolve the thrombus, or thromboembolism despite optimal OAC, there are limited nonsurgical options.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To introduce a novel management strategy for resistant LAA thrombus: percutaneous mechanical thrombus aspiration with cerebral protection, followed by LAA closure (LAAC).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This descriptive, prospective case series of 9 consecutive patients with persistent LAA thrombus was conducted between August 2023 and July 2024 at Mount Sinai Hospital. After placing a cerebral protection device (CPD) when anatomically feasible, balloon atrial septostomy was performed as needed to enhance transeptal access. A 20F mechanical aspiration device with a 15-mm funneled ostium was advanced to the LAA ostium, and manual vacuum aspiration of thrombus was performed. After ultrasonic confirmation of thrombectomy, an LAAC device was implanted.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Patient demographic, clinical, and intervention data were collected.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Nine patients (mean [SD] age, 74.7 [13.6] years; median [IQR] CHA2DS2-VASc [congestive heart failure, hypertension, age 75 years or older, diabetes, stroke, vascular disease, age 65-74 years, and female sex] score, 5 [2-8] points) presented with LAA thrombus in the context of contraindications to OAC. CPD was placed in 8 patients; one had prohibitive aortic arch anatomy. Given the patient's high thrombotic burden and limited alternatives, the decision was to proceed without CPD, based on a risk-benefit assessment. Balloon atrial septostomy was performed in 8 patients. In 8 patients, complete thrombus removal was achieved, followed by successful LAAC device placement. One patient had a small residual distal thrombus, presumably organized, which was strongly adherent to the LAA myocardium; this was compressed against the wall with the LAAC device. One patient had a small thrombus fragment recovered from the CPD postprocedure. During both the index procedure and during follow-up (range, 4-15 months), there were no complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This cases series found that temporary cerebral protection, percutaneous mechanical vacuum thrombectomy, and mechanical LAA closure was feasible in patients with persistent LAA thrombus despite optimal OAC. Larger studies will be needed to fully assess the efficacy and safety of this approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105811/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105811</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0203>10.1001/jamacardio.2025.0203</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105811</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Maryam Saleem</dc:creator>
<dc:creator>Abhishek Maan</dc:creator>
<dc:creator>Daniel R Musikantow</dc:creator>
<dc:creator>Chi Zhang</dc:creator>
<dc:creator>Yury Malyshev</dc:creator>
<dc:creator>Marc A Miller</dc:creator>
<dc:creator>Srinivas R Dukkipati</dc:creator>
<dc:creator>Parasuram M Krishnamoorthy</dc:creator>
<dc:creator>Martin Goldman</dc:creator>
<dc:creator>Prakash Krishnan</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Concomitant Mechanical Aspiration and Appendage Closure for Recalcitrant Left Atrial Appendage Thrombi</dc:title>
<dc:identifier>pmid:40105811</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0203</dc:identifier>
</item>
<item>
<title>JAMA Cardiology-The Year in Review 2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40105806/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 19. doi: 10.1001/jamacardio.2025.0478. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40105806/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40105806</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0478>10.1001/jamacardio.2025.0478</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40105806</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology-The Year in Review 2024</dc:title>
<dc:identifier>pmid:40105806</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0478</dc:identifier>
</item>
<item>
<title>Progression of Atrial Cardiomyopathy Predicts Subsequent Stroke: An Analysis of Left Atrial Low-Voltage Areas in Patients With Atrial Fibrillation Ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40104861/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Arrhythm Electrophysiol. 2025 Mar 19:e013550. doi: 10.1161/CIRCEP.124.013550. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40104861/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40104861</a> | DOI:<a href=https://doi.org/10.1161/CIRCEP.124.013550>10.1161/CIRCEP.124.013550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40104861</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yasuhiro Matsuda</dc:creator>
<dc:creator>Satoshi Kudo</dc:creator>
<dc:creator>Masaharu Masuda</dc:creator>
<dc:creator>Hiroyuki Uematsu</dc:creator>
<dc:creator>Ayako Sugino</dc:creator>
<dc:creator>Hirotaka Ooka</dc:creator>
<dc:creator>Subaru Fujii</dc:creator>
<dc:creator>Shin Okamoto</dc:creator>
<dc:creator>Takayuki Ishihara</dc:creator>
<dc:creator>Kiyonori Nanto</dc:creator>
<dc:creator>Takuya Tsujimura</dc:creator>
<dc:creator>Yosuke Hata</dc:creator>
<dc:creator>Sho Nakao</dc:creator>
<dc:creator>Masaya Kusuda</dc:creator>
<dc:creator>Wataru Ariyasu</dc:creator>
<dc:creator>Toshiaki Mano</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>Circulation. Arrhythmia and electrophysiology</dc:source>
<dc:title>Progression of Atrial Cardiomyopathy Predicts Subsequent Stroke: An Analysis of Left Atrial Low-Voltage Areas in Patients With Atrial Fibrillation Ablation</dc:title>
<dc:identifier>pmid:40104861</dc:identifier>
<dc:identifier>doi:10.1161/CIRCEP.124.013550</dc:identifier>
</item>
<item>
<title>Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40104858/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The LRA was associated with significantly less cumulative and normalized radiation exposure to the thorax, abdomen, left eye, and right eye of the primary operator compared with HARRA during diagnostic cardiac catheterization. Operators should consider using LRA more frequently than HARRA for diagnostic cardiac catheterization as this approach can reduce occupational radiation exposure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar 19:e014602. doi: 10.1161/CIRCINTERVENTIONS.124.014602. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Radiation exposure is one of the most adverse occupational hazards faced by interventional cardiologists. Various arterial access sites have shown to yield different operator radiation exposure during diagnostic cardiac catheterization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This single-center randomized controlled trial assessed the cumulative radiation exposure and normalized radiation exposure at 4 different anatomic locations (thorax, abdomen, left eye, and right eye) of the primary operator when using the left radial artery (LRA) approach compared with a uniform hyper-adducted right radial artery (HARRA) approach. Patients (n=534) were randomized to LRA (n=269) or HARRA (n=265). During diagnostic catheterization, real-time radiation dosimeters were placed on the thorax, abdomen, left eye, and right eye of each operator.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cumulative radiation measurements were as follows: thorax (LRA, 9.66±8.57 microsieverts [μSv] versus HARRA, 12.27±7.09 μSv; <i>P</i>&lt;0.001); abdomen (LRA, 27.46±21.20 μSv versus HARRA, 36.56±23.72 μSv; <i>P</i>&lt;0.001); left eye (LRA, 2.65±2.59 μSv versus HARRA, 3.77±2.67 μSv; <i>P</i>&lt;0.001); and right eye (LRA, 1.13±1.69 μSv versus HARRA, 1.44±1.62 μSv; <i>P</i>=0.01). Normalized radiation measurements were: thorax (LRA, 0.38±0.35 versus HARRA, 0.49±0.24; <i>P</i>&lt;0.001); abdomen (LRA, 1.06±0.72 versus HARRA, 1.38±0.69; <i>P</i>&lt;0.001); left eye (LRA, 0.10±0.09 versus HARRA, 0.15±0.10; <i>P</i>&lt;0.001); and right eye: (LRA, 0.04±0.06 versus HARRA, 0.05±0.06; <i>P</i>=0.02). LRA had lower subclavian tortuosity than HARRA (15.6% versus 32.5%, <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The LRA was associated with significantly less cumulative and normalized radiation exposure to the thorax, abdomen, left eye, and right eye of the primary operator compared with HARRA during diagnostic cardiac catheterization. Operators should consider using LRA more frequently than HARRA for diagnostic cardiac catheterization as this approach can reduce occupational radiation exposure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05833516.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40104858/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40104858</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014602>10.1161/CIRCINTERVENTIONS.124.014602</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40104858</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Richard Casazza</dc:creator>
<dc:creator>Bilal Malik</dc:creator>
<dc:creator>Arsalan Hashmi</dc:creator>
<dc:creator>Joshua Fogel</dc:creator>
<dc:creator>Enrico Montagna</dc:creator>
<dc:creator>Robert Frankel</dc:creator>
<dc:creator>Elliot Borgen</dc:creator>
<dc:creator>Sergey Ayzenberg</dc:creator>
<dc:creator>Michael Friedman</dc:creator>
<dc:creator>Norbert Moskovits</dc:creator>
<dc:creator>Shivani Verma</dc:creator>
<dc:creator>Jamie Meng</dc:creator>
<dc:creator>Nailun Chang</dc:creator>
<dc:creator>Yili Huang</dc:creator>
<dc:creator>Carlos Rodriguez</dc:creator>
<dc:creator>Habib Hymie Chera</dc:creator>
<dc:creator>Shiv Raj</dc:creator>
<dc:creator>Saurav Chaterjee</dc:creator>
<dc:creator>Daren Gibson</dc:creator>
<dc:creator>Andres Palacios</dc:creator>
<dc:creator>Chirag Agarwal</dc:creator>
<dc:creator>Maria Victoria Nene</dc:creator>
<dc:creator>Jacob Shani</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Operator Radiation Exposure Comparing the Left Radial Artery Approach and a Uniform Hyper-Adducted Right Radial Artery Approach: The HARRA Study</dc:title>
<dc:identifier>pmid:40104858</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014602</dc:identifier>
</item>
<item>
<title>Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40104841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 19. doi: 10.1161/CIR.0000000000001308. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The field of cardio-oncology has expanded over the past 2 decades to address the ever-increasing issues related to cardiovascular disease in patients with cancer and survivors. There is increasing recognition that nearly all cancer treatments pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Anthracycline chemotherapy and chest-directed radiotherapy are the most well-studied cardiotoxic therapies, and dose reduction, use of cardioprotection for anthracyclines, and modern radiotherapy approaches have contributed to improved cardiovascular outcomes for survivors. Newer treatments such as small-molecule inhibitors, antibody-based cytotoxic therapy, and immunotherapy have expanded options for previously difficult-to-treat cancers but have also revealed new cardiotoxic profiles. Application of effective surveillance strategies in patients with cancer and survivors has been a focus of practitioners and researchers, whereas the prevention and treatment of extant cardiovascular disease is still developing. Incorporation of new strategies in an equitable manner and appropriate transition from pediatric to adult care will greatly influence long-term health-related outcomes in the growing population of childhood cancer survivors at risk for cardiovascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40104841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40104841</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001308>10.1161/CIR.0000000000001308</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40104841</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Thomas D Ryan</dc:creator>
<dc:creator>James E Bates</dc:creator>
<dc:creator>Karen E Kinahan</dc:creator>
<dc:creator>Kasey J Leger</dc:creator>
<dc:creator>Daniel A Mulrooney</dc:creator>
<dc:creator>Hari K Narayan</dc:creator>
<dc:creator>Kirsten Ness</dc:creator>
<dc:creator>Tochukwu M Okwuosa</dc:creator>
<dc:creator>Nino C Rainusso</dc:creator>
<dc:creator>Julia Steinberger</dc:creator>
<dc:creator>Saro H Armenian</dc:creator>
<dc:creator>Pediatric Heart Failure &amp; Transplantation Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40104841</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001308</dc:identifier>
</item>
<item>
<title>Balloon-expandable stent and self-expandable stent combined to treat coarctation of the aorta with descending aortic aneurysm: a case report</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103801/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Coarctation of the aorta is often associated with aortic dilatation, presenting a complex challenge for stent-based interventions. To address this, we have developed a novel combination of stent treatments to manage this dual pathology effectively.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 18;9(3):ytaf094. doi: 10.1093/ehjcr/ytaf094. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coarctation of the aorta is often associated with aortic dilatation, presenting a complex challenge for stent-based interventions. To address this, we have developed a novel combination of stent treatments to manage this dual pathology effectively.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: A 29-year-old hypertensive patient with a coarctation of the aorta and a descending thoracic aortic aneurysm was evaluated for treatment. Contrast-enhanced computed tomography angiography (CTA) revealed significant narrowing at the aortic arch (Zone 2, proximal to the left subclavian artery) with a diameter of 5.04 mm. Additionally, the descending aorta had an aneurysmal dilation measuring 29.65 mm. We applied an innovative approach combining a balloon-expandable stent (BES) with a self-expandable stent (SES). Post-procedure CTA demonstrated favourable aortic remodelling, with the narrowest point of the aorta expanding from 5.04 to 15.95 mm.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: This novel technique of implanting a BES within an SES effectively addresses both the aortic coarctation and the descending aortic aneurysm. By tripling the diameter of the coarctation, the approach maximizes aortic expansion while protecting the aorta. Moreover, the combination of these stents enhances overall stability, reducing the risk of stent migration or displacement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103801/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40103801</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11914319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">PMC11914319</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf094>10.1093/ehjcr/ytaf094</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103801</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Xiaoxue Zhang</dc:creator>
<dc:creator>Shiliang Li</dc:creator>
<dc:creator>Xiantao Ma</dc:creator>
<dc:creator>Wajeehullahi Akilu</dc:creator>
<dc:creator>Cai Cheng</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Balloon-expandable stent and self-expandable stent combined to treat coarctation of the aorta with descending aortic aneurysm: a case report</dc:title>
<dc:identifier>pmid:40103801</dc:identifier>
<dc:identifier>pmc:PMC11914319</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf094</dc:identifier>
</item>
<item>
<title>Left atrial veno-arterial extracorporeal membrane oxygenation as a bridge to surgical or percutaneous closure of post-myocardial infarction ventriculoseptal defects: a case series</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103800/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Post-myocardial infarct (MI) ventricular septal defect (VSD) is a rare and severe complication of an acute MI with high mortality rate. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to surgical or percutaneous repair in cardiogenic shock secondary to post-MI-VSD has been published, but is limited to small case series primarily utilizing surgical ECMO, with the main drawback of potentially increasing afterload and left ventricle pressure, further...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 25;9(3):ytaf095. doi: 10.1093/ehjcr/ytaf095. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Post-myocardial infarct (MI) ventricular septal defect (VSD) is a rare and severe complication of an acute MI with high mortality rate. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) as a bridge to surgical or percutaneous repair in cardiogenic shock secondary to post-MI-VSD has been published, but is limited to small case series primarily utilizing surgical ECMO, with the main drawback of potentially increasing afterload and left ventricle pressure, further worsening VSD shunting. Left-atrial VA-ECMO (LAVA-ECMO) can potentially absolve this concern given that it utilizes bi-atrial drainage through a trans-septal fenestrated cannula.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: Five patients were included in this series, all with VSD secondary to MI, and all managed with LAVA-ECMO as a bridge to repair. Average age was 62 ± 4.2 years, body mass index of 29.4 ± 4.5 kg/m<sup>2</sup>, and left ventricular ejection fraction of 46.6 ± 13.8%. Haemodynamics monitoring pre- and post-LAVA-ECMO demonstrated improvement in right atrial, right ventricular, pulmonary, left atrial, and left ventricular pressures (<i>Figure 1</i>). Average time to repair was 7.4 ± 3.9 days. All five patients survived to repair, with four undergoing surgical and one undergoing percutaneous closure. Four out of five patients were decannulated successfully.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: This case series reports the successful use of LAVA-ECMO as a bridge to MI-VSD repair in patients with cardiogenic shock. Left-atrial VA-ECMO serves as a convenient approach to managing patients with MI-VSD related cardiogenic shock as it is implanted percutaneously, and can be done at the time of shock diagnosis, during right heart catheterization by trained interventionists.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103800/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40103800</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11914317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">PMC11914317</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf095>10.1093/ehjcr/ytaf095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103800</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Raef Fadel</dc:creator>
<dc:creator>Jessica Elderkin</dc:creator>
<dc:creator>Hussayn Alrayes</dc:creator>
<dc:creator>Gennaro Giustino</dc:creator>
<dc:creator>Tiberio Frisoli</dc:creator>
<dc:creator>Mir Babar Basir</dc:creator>
<dc:creator>Dimitrios Apostolou</dc:creator>
<dc:creator>Pedro Villablanca</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Left atrial veno-arterial extracorporeal membrane oxygenation as a bridge to surgical or percutaneous closure of post-myocardial infarction ventriculoseptal defects: a case series</dc:title>
<dc:identifier>pmid:40103800</dc:identifier>
<dc:identifier>pmc:PMC11914317</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf095</dc:identifier>
</item>
<item>
<title>Possible solution for coronary cannulation through complete anti-anatomical deployment of self-expandable transcatheter heart valve using handmade spiral curve of catheter created by heat-gun</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103799/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Mar 18;9(3):ytaf011. doi: 10.1093/ehjcr/ytaf011. eCollection 2025 Mar.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103799/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40103799</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11913563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">PMC11913563</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf011>10.1093/ehjcr/ytaf011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103799</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Masanori Yamamoto</dc:creator>
<dc:creator>Hirooki Higami</dc:creator>
<dc:creator>Yuki Kondo</dc:creator>
<dc:creator>Fubuki Kitahara</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Possible solution for coronary cannulation through complete anti-anatomical deployment of self-expandable transcatheter heart valve using handmade spiral curve of catheter created by heat-gun</dc:title>
<dc:identifier>pmid:40103799</dc:identifier>
<dc:identifier>pmc:PMC11913563</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf011</dc:identifier>
</item>
<item>
<title>Haemodynamic spectrum in heritable pulmonary arterial hypertension: a continuum from pre-capillary to combined pulmonary hypertension-case series</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40103798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>BACKGROUND: Heritable pulmonary arterial hypertension (PAH) is a rare form of pre-capillary pulmonary hypertension that typically affects young patients. With increased survival and subsequent ageing of these patients, newly acquired cardiovascular conditions may influence the pulmonary haemodynamic profile and impact management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Case Rep. 2025 Feb 26;9(3):ytaf109. doi: 10.1093/ehjcr/ytaf109. eCollection 2025 Mar.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heritable pulmonary arterial hypertension (PAH) is a rare form of pre-capillary pulmonary hypertension that typically affects young patients. With increased survival and subsequent ageing of these patients, newly acquired cardiovascular conditions may influence the pulmonary haemodynamic profile and impact management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CASE SUMMARY: We report a case series of four patients with mutations in genes associated with PAH to illustrate the spectrum of pulmonary haemodynamics under the influence of superimposed acquired conditions. The first two cases involve patients with a long-standing diagnosis of heritable PAH and severe pre-capillary pulmonary hypertension, who developed overt left-sided diastolic dysfunction later in follow-up due to the acquisition of multiple cardiovascular comorbidities. The second two cases describe patients with a genetic pre-disposition to develop PAH and conditions that are risk factors for left heart disease, with mild elevation of resting pulmonary pressures, in whom exercise right heart catheterization unmasked occult left-sided diastolic dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DISCUSSION: Pulmonary haemodynamics are complex and dynamic over time, even in patients with or at risk of heritable PAH, when additional acquired cardiovascular conditions emerge. Correct phenotyping at diagnosis and during follow-up of patients at risk of heritable PAH, along with a clear understanding of the underlying pulmonary haemodynamic profile, is crucial for appropriate management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40103798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40103798</a> | PMC:<a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11913607/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">PMC11913607</a> | DOI:<a href=https://doi.org/10.1093/ehjcr/ytaf109>10.1093/ehjcr/ytaf109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40103798</guid>
<pubDate>Wed, 19 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Irene Martín de Miguel</dc:creator>
<dc:creator>Alejandro Cruz Utrilla</dc:creator>
<dc:creator>Teresa Segura de La Cal</dc:creator>
<dc:creator>Fernando Sarnago Cebada</dc:creator>
<dc:creator>Maite Velázquez Martín</dc:creator>
<dc:creator>Carmen Jiménez López-Guarch</dc:creator>
<dc:creator>Fernando Arribas Ynsaurriaga</dc:creator>
<dc:creator>Pilar Escribano Subías</dc:creator>
<dc:date>2025-03-19</dc:date>
<dc:source>European heart journal. Case reports</dc:source>
<dc:title>Haemodynamic spectrum in heritable pulmonary arterial hypertension: a continuum from pre-capillary to combined pulmonary hypertension-case series</dc:title>
<dc:identifier>pmid:40103798</dc:identifier>
<dc:identifier>pmc:PMC11913607</dc:identifier>
<dc:identifier>doi:10.1093/ehjcr/ytaf109</dc:identifier>
</item>
<item>
<title>Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40101708/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>Lymphocyte activation gene 3 (LAG3) has emerged as a promising cancer immunotherapy target, but the mechanism underlying LAG3 activation upon ligand engagement remains elusive. Here, LAG3 was found to undergo robust non-K48-linked polyubiquitination upon ligand engagement, which promotes LAG3's inhibitory function instead of causing degradation. This ubiquitination could be triggered by the engagement of major histocompatibility complex class II (MHC class II) and membrane-bound (but not...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 6:S0092-8674(25)00199-0. doi: 10.1016/j.cell.2025.02.014. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Lymphocyte activation gene 3 (LAG3) has emerged as a promising cancer immunotherapy target, but the mechanism underlying LAG3 activation upon ligand engagement remains elusive. Here, LAG3 was found to undergo robust non-K48-linked polyubiquitination upon ligand engagement, which promotes LAG3's inhibitory function instead of causing degradation. This ubiquitination could be triggered by the engagement of major histocompatibility complex class II (MHC class II) and membrane-bound (but not soluble) fibrinogen-like protein 1 (FGL1). LAG3 ubiquitination, mediated redundantly by the E3 ligases c-Cbl and Cbl-b, disrupted the membrane binding of the juxtamembrane basic residue-rich sequence, thereby stabilizing the LAG3 cytoplasmic tail in a membrane-dissociated conformation enabling signaling. Furthermore, LAG3 ubiquitination is crucial for the LAG3-mediated suppression of antitumor immunity in vivo. Consistently, LAG3 therapeutic antibodies repress LAG3 ubiquitination, correlating with their checkpoint blockade effects. Moreover, patient cohort analyses suggest that LAG3/CBL coexpression could serve as a biomarker for response to LAG3 blockade. Collectively, our study reveals an immune-checkpoint-triggering mechanism with translational potential in cancer immunotherapy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40101708/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40101708</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.014>10.1016/j.cell.2025.02.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40101708</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yong Jiang</dc:creator>
<dc:creator>Anran Dai</dc:creator>
<dc:creator>Yuwei Huang</dc:creator>
<dc:creator>Hua Li</dc:creator>
<dc:creator>Jian Cui</dc:creator>
<dc:creator>Haochen Yang</dc:creator>
<dc:creator>Lu Si</dc:creator>
<dc:creator>Tao Jiao</dc:creator>
<dc:creator>Zhengxu Ren</dc:creator>
<dc:creator>Ziwei Zhang</dc:creator>
<dc:creator>Si Mou</dc:creator>
<dc:creator>Hengrui Zhu</dc:creator>
<dc:creator>Wenhui Guo</dc:creator>
<dc:creator>Qiang Huang</dc:creator>
<dc:creator>Yilin Li</dc:creator>
<dc:creator>Manman Xue</dc:creator>
<dc:creator>Jingwei Jiang</dc:creator>
<dc:creator>Fei Wang</dc:creator>
<dc:creator>Li Li</dc:creator>
<dc:creator>Qinying Zhong</dc:creator>
<dc:creator>Kun Wang</dc:creator>
<dc:creator>Baichuan Liu</dc:creator>
<dc:creator>Jinjiao Wang</dc:creator>
<dc:creator>Gaofeng Fan</dc:creator>
<dc:creator>Jun Guo</dc:creator>
<dc:creator>Liang Chen</dc:creator>
<dc:creator>Creg J Workman</dc:creator>
<dc:creator>Zhirong Shen</dc:creator>
<dc:creator>Yan Kong</dc:creator>
<dc:creator>Dario A A Vignali</dc:creator>
<dc:creator>Chenqi Xu</dc:creator>
<dc:creator>Haopeng Wang</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs</dc:title>
<dc:identifier>pmid:40101708</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.014</dc:identifier>
</item>
<item>
<title>Left atrial intramural hematoma after ventricular radiofrequency catheter ablation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J Cardiovasc Imaging. 2025 Mar 18:jeaf091. doi: 10.1093/ehjci/jeaf091. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40101156/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40101156</a> | DOI:<a href=https://doi.org/10.1093/ehjci/jeaf091>10.1093/ehjci/jeaf091</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40101156</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Alan Diniz Hummel</dc:creator>
<dc:creator>André Vaz</dc:creator>
<dc:creator>André Paciello Romualdo</dc:creator>
<dc:creator>Andrei Skromov de Albuquerque</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>European heart journal. Cardiovascular Imaging</dc:source>
<dc:title>Left atrial intramural hematoma after ventricular radiofrequency catheter ablation</dc:title>
<dc:identifier>pmid:40101156</dc:identifier>
<dc:identifier>doi:10.1093/ehjci/jeaf091</dc:identifier>
</item>
<item>
<title>Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e014243. doi: 10.1161/CIRCINTERVENTIONS.124.014243. Epub 2025 Mar 18.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Neonates with hypoplastic left heart syndrome variants with an intact or highly restrictive atrial septum (HLH-IAS) require immediate postnatal intervention to survive. Emergent left atrial decompression (LAD) via a percutaneous or hybrid approach is standard, but the comparative effectiveness and outcomes of these approaches remain underexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A multicenter retrospective analysis of all neonates with HLH-IAS who underwent LAD in the first 36 hours of life from January 2009 to March 2020 at 14 North American congenital cardiac programs was conducted. Patient and procedural characteristics and patient outcomes were compared between hybrid and percutaneous LAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 128 patients with HLH-IAS, 105 (80%) underwent percutaneous LAD and 23 (17%) hybrid LAD. No significant differences were observed in preprocedural characteristics such as birth weight (3.1±0.6 versus 3.2±0.6 kg; <i>P</i>=0.453), presence of a baseline interatrial communication (66% versus 61%; <i>P</i>=0.659), interatrial communication gradient (14.4±6.9 versus 12.7±4.6 mm Hg; <i>P</i>=0.456), or lowest pH (7.13±0.14 versus 7.09±0.15; <i>P</i>=0.193). Hybrid LAD resulted in a shorter time from birth to procedure (120 versus 52 minutes; <i>P</i>=0.005) and to atrial septal defect creation (55 versus 29 minutes; <i>P</i>=0.002). All hybrid LAD were technically successful, although 11 (10%) percutaneous LAD were unsuccessful with 7 requiring conversion to surgical septectomy. There was a trend toward fewer serious adverse events with hybrid LAD (36% versus 17%; <i>P</i>=0.141). Most patients (67%) who underwent hybrid LAD had simultaneous pulmonary artery band placement and 21% of patients with percutaneous LAD required reoperation for pulmonary artery band. Long-term survival rates were comparably low between groups, with a 30% transplant-free survival at a median 8-month follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HLH-IAS, hybrid LAD allows for faster atrial septal defect creation, has a higher technical success rate, and potentially fewer procedural serious adverse events compared with percutaneous LAD, alongside facilitating simultaneous pulmonary artery band. Our findings underscore the poor prognosis for patients with HLH-IAS despite intervention, highlighting the need for better treatment strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40100953</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.124.014243>10.1161/CIRCINTERVENTIONS.124.014243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100953</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Konstantin Averin</dc:creator>
<dc:creator>Michael D Seckeler</dc:creator>
<dc:creator>Holly Bauser-Heaton</dc:creator>
<dc:creator>Matthew C Schwartz</dc:creator>
<dc:creator>Paul Tannous</dc:creator>
<dc:creator>Cameron Seaman</dc:creator>
<dc:creator>Wendy Whiteside</dc:creator>
<dc:creator>George T Nicholson</dc:creator>
<dc:creator>Priti M Patel</dc:creator>
<dc:creator>Brent M Gordon</dc:creator>
<dc:creator>Ryan A Romans</dc:creator>
<dc:creator>Rajiv Devanagondi</dc:creator>
<dc:creator>Carrie E Herbert</dc:creator>
<dc:creator>Sarosh P Batlivala</dc:creator>
<dc:creator>Brian Boe</dc:creator>
<dc:creator>Gurumurthy Hiremath</dc:creator>
<dc:creator>Jeffrey D Zampi</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>Hybrid Versus Percutaneous Left Atrial Decompression in Infants With Hypoplastic Left Heart Variants and an Intact or Highly Restrictive Atrial Septum: A Multicenter PICES Study</dc:title>
<dc:identifier>pmid:40100953</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.124.014243</dc:identifier>
</item>
<item>
<title>PCI for Surgically Ineligible Patients: Another Piece of the Jigsaw</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250319141610&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Cardiovasc Interv. 2025 Mar;18(3):e015200. doi: 10.1161/CIRCINTERVENTIONS.125.015200. Epub 2025 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40100952/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250319141610&v=2.18.0.post9+e462414">40100952</a> | DOI:<a href=https://doi.org/10.1161/CIRCINTERVENTIONS.125.015200>10.1161/CIRCINTERVENTIONS.125.015200</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40100952</guid>
<pubDate>Tue, 18 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Tim Kinnaird</dc:creator>
<dc:date>2025-03-18</dc:date>
<dc:source>Circulation. Cardiovascular interventions</dc:source>
<dc:title>PCI for Surgically Ineligible Patients: Another Piece of the Jigsaw</dc:title>
<dc:identifier>pmid:40100952</dc:identifier>
<dc:identifier>doi:10.1161/CIRCINTERVENTIONS.125.015200</dc:identifier>
</item>





























</channel>
</rss>